# A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease

> **NCT04619420** · PHASE2 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 523 (actual)

## Conditions studied

- Alzheimer Disease
- Cognitive Dysfunction
- Dementia

## Interventions

- **DRUG:** JNJ-63733657
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04619420
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-06
- **Primary completion:** 2025-10-17
- **Final completion:** 2026-03-03
- **Target enrollment:** 523 (ACTUAL)
- **Why stopped:** Posdinemab did not achieve statistical significance in slowing clinical decline
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04619420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04619420, "A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04619420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*